Predictive Factors of Persistence in Therapy with Abatacept in Patients with Rheumatoid Arthritis

Trial Profile

Predictive Factors of Persistence in Therapy with Abatacept in Patients with Rheumatoid Arthritis

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2016

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Feb 2016 New trial record
    • 01 Dec 2014 Recruitment completed according to results presented at the 17th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top